2-(1-咪唑基)乙酸甲酯 | 25023-22-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(1-咪唑基)乙酸甲酯
• 中文别名: 2-(咪唑-1-基)乙酸甲酯
• 英文名称: methyl imidazol-1-ylacetate
• 英文别名: Methyl 1H-imidazol-1-ylacetate；methyl 2-imidazol-1-ylacetate
• CAS: 25023-22-7
• 化学式: C₆H₈N₂O₂
• mdl: MFCD11183411
• 分子量: 140.142
• InChiKey: MENQOXBTQWXPJA-UHFFFAOYSA-N

物化性质

• 熔点：
  55 °C
• 沸点：
  282.5±23.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1h-imidazol-1-ylacetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1h-imidazol-1-ylacetate
CAS number: 25023-22-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8N2O2
Molecular weight: 140.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(1-咪唑基)乙酸甲酯 在 水 作用下， 反应 6.0h， 生成 咪唑-1-乙酸
  参考文献：
  名称：

  3-D QSAR研究双膦酸盐对利什曼原虫主要法呢基焦磷酸合酶的抑制作用。

  摘要：

  我们报告了作为利什曼原虫主要甲羟戊酸/异戊二烯生物合成途径酶，法呢基焦磷酸合酶的抑制剂的62二膦酸盐的活性。所研究的化合物具有约100 nM至约80 microM（相当于K（i）值低至10 nM）的活性（IC（50）值）。发现活性最高的化合物是唑来膦酸盐（据报道其单晶X射线结构），吡啶基-乙烷-1-羟基-1,1-双膦酸酯或吡啶甲基氨基亚甲基双膦酸酯。但是，N-脂环族氨基亚甲基双膦酸酯（如茚满膦酸酯）（N-环庚基氨基亚甲基双膦酸酯）以及含有短（n = 4、5）烷基链的脂族氨基亚甲基双膦酸酯也具有活性，IC（50）值在200-1700 nM范围内（对应于大约20-170 nM的K（i）值）。含有更长或多个（N，N-）烷基取代基的双膦酸酯是无活性的，环上缺少邻或间氮原子或具有多个卤素取代基或对氨基的芳香族化合物也是如此。为了将这些观察结果放在更定量的结构基础上，我们使用了三维定量结构-活性关系技

  DOI：

  10.1021/jm0302344
• 作为产物：
  描述：

  咪唑 、 溴乙酸甲酯 在 potassium carbonate 、 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 7.0h， 以77%的产率得到2-(1-咪唑基)乙酸甲酯
  参考文献：
  名称：

  开发咪唑链烷酸作为mGAT3选择性GABA摄取抑制剂

  摘要：

  合成了一系列新的潜在的GABA吸收抑制剂，这些抑制剂从1 H-咪唑-4-基乙酸开始，羧酸侧链来自不同的位置，且长度不同，并在四个GABA吸收转运蛋白mGAT1上测试了其抑制能力。 –4在HEK细胞中稳定表达。这项研究还包括了另外两个带有刚性羧酸侧链的双环化合物。生物学测试的结果表明，大多数ω-咪唑链烷酸和链烯酸衍生物作为mGAT3的GABA吸收抑制剂表现出最高的效力。

  DOI：

  10.1016/j.ejmech.2011.01.042

文献信息

• Synthesis and Regioselective Hydrolysis of 2-(Imidazol-1-yl)succinic Esters
  作者：Paula Zaderenko、M. Soledad Gil、Paloma Ballesteros、Sebastian Cerdan

  DOI：10.1021/jo00100a030

  日期：1994.10

  (+/-)-2-Imidazol-1-ylsuccinic esters were synthesized by thermal addition of imidazole to either fumaric or maleic esters. Acceleration of the reaction was achieved, in some cases, using microwave heating. These esters underwent an easy regioselective hydrolysis, under neutral conditions, to give the corresponding half-esters: (+/-)-3-(alkoxycarbonyl)-2-imidazol-1-ylpropionic acids, through either BAC(3) or BAL(1) mechanisms. Kinetic studies in H2O and D2O as well as O-18 and O-17 labeling experiments supported the proposed mechanism. The results of these hydrolyses, which depended on the nature of the alcohol moiety, were compared with those obtained with some imidazol-1-ylacetate analogues or with (+/-)-2-pyrazol-1-yl- and benzimidazol-1-ylsuccinic esters. In general, imidazolylsuccinic esters hydrolyzed faster than the homologous derivatives from pyrazole or benzimidazole.

  (±)-2-咪唑-1-基琥珀酸酯是通过将咪唑与富马酸酯或马来酸酯在热条件下进行加成反应而合成的。在某些情况下，通过微波加热可以加速反应进程。这些酯在中性条件下经历一种简单的区域选择性水解，生成相应的半酯：(±)-3-(烷氧基羰基)-2-咪唑-1-基丙二酸，其水解机制可能涉及BAC(3)或BAL(1)路径。在H2O和D2O中的动力学研究，以及O-18和O-17的标记实验结果，均支持了所提出的水解机制。这些水解产物的性质依赖于醇基的类型，与一些咪唑-1-基丙二酸酯类似物，或与(±)-2-吡唑-1-基和苯并咪唑-1-基琥珀酸酯的水解结果进行比较。总体而言，咪唑基琥珀酸酯的水解速度比来自吡唑或苯并咪唑的同类衍生物更快。
• Benzoamide piperidine containing compounds and related compounds
  申请人：——

  公开号：US20030087925A1

  公开（公告）日：2003-05-08

  The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

  本发明涉及某些含有苯甲酰胺哌啶类化合物和相关化合物，这些化合物表现出作为NK-1受体拮抗剂（例如，物质P受体拮抗剂）的活性，以及含有它们的药物组合物，以及它们在治疗和预防中枢神经系统疾病、炎症性疾病、心血管疾病、眼科疾病、消化系统疾病、幽门螺杆菌引起的疾病、免疫系统疾病、尿失禁、疼痛、偏头痛、呕吐、血管生成和其他疾病的治疗中的用途。
• [EN] LIPID NANOPARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE NANOPARTICULES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018081480A1

  公开（公告）日：2018-05-03

  Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

  提供了改进的脂质纳米粒子配方。还提供了利用这些脂质纳米粒子传递治疗剂的方法以及它们的制备方法。
• [EN] LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS<br/>[FR] LIPIDES ET FORMULATIONS DE NANOPARTICULES DE LIPIDES POUR LA LIBÉRATION D'ACIDES NUCLÉIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2017117528A1

  公开（公告）日：2017-07-06

  Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或（II）的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中R、R1、R2、L、X、L、G1、G2、Z、a1、a2和n分别如本文所定义的用于结构（I）和（II）。还提供了将这些化合物用作脂质纳米粒子配方的组分以传递治疗剂、包含这些化合物的组合物以及其使用和制备方法。
• Process for Making Zoledronic Acid
  申请人：Kas Martin

  公开号：US20100130746A1

  公开（公告）日：2010-05-27

  Processes for making zoledronic acid can be advantageously carried out in a solvent/diluent that comprises a mixture of (i) a polyalkylene glycol and (ii) a cyclic carbonate of the formula (3) wherein n is an integer from 2 to 4, and R 1 and R 2 each independently represent a hydrogen or a C1-C4 alkyl group.

  制备左氧磷酸的过程可以有利地在包含以下混合物的溶剂/稀释剂中进行：(i) 聚烷基二醇和(ii) 公式(3)中的环碳酸酯的混合物，其中n是2到4之间的整数，R1和R2各自独立表示氢或C1-C4烷基基团。